Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

With­in hours of is­su­ing word that Bridge­Bio $BBIO had pulled in $90 mil­lion from its SHP2 li­cens­ing deal with Bris­tol My­ers Squibb, CEO Neil Ku­mar had fi­nal­ized an­oth­er deal to sell their pri­or­i­ty re­view vouch­er for $110 mil­lion.

Not un­usu­al in PRV sales, the biotech is keep­ing the pur­chas­er’s name un­der wraps, but Ku­mar — who’s been re­struc­tur­ing the com­pa­ny, part­ner­ing pro­grams, lay­ing off staffers and look­ing to do deals to keep the ship right­ed dur­ing a stormy biotech tem­pest on Wall Street — was more than hap­py to dis­cuss the lat­est wind­fall to come his way “at a re­al­ly at­trac­tive price.”

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE